Wednesday, July 8, 2026

Patent intelligence · US

US 8841120

Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity

granted A61KA61K2039/5258A61K2039/543A61K2039/55505
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 8
Applicant portfolio 1,436
Patent details — US 8841120
Jurisdiction
US
Status
granted
Grant date
Sep 23, 2014
Expiration
Sep 18, 2034
Claims
35
CPC classes
A61K, A61K2039/5258, A61K2039/543, A61K2039/55505
View on Google Patents ↗

Quick answer

US 8841120 (Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity) is held by Takeda Vaccines, Inc.. Status: granted. Granted Sep 23, 2014. Expires Sep 18, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
35
CPC classes
A61K, A61K2039/5258, A61K2039/543, A61K2039/55505, A61K2039/55572, A61K2039/55583

More from Takeda Vaccines, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 8841120?

US 8841120 (Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity) is held by Takeda Vaccines, Inc.. Status: granted. Granted Sep 23, 2014. Expires Sep 18, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8841120?

Takeda Vaccines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 8841120 expire?

Our index shows an expiration date of Sep 18, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.